Management of narcolepsy during pregnancy

Sleep Medicine

Volumn 14, Issue 4, 2013, Pages 367-376

  Thorpy, Michael ^c   Zhao, Chi George ^a   Dauvilliers, Yves ^b  

^a not available   (United States)

^b GUI DE CHAULIAC HOSPITAL   (France)

^c MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Breast feeding; Caesarian; Cataplexy; Conception; Congenital abnormalities; Delivery; Foetus; Lactation; Narcolepsy; Pregnancy; Terogenicity

Indexed keywords

4 HYDROXYBUTYRIC ACID; AMPHETAMINE; ANTIDEPRESSANT AGENT; ARMODAFINIL; CLOMIPRAMINE; FLUOXETINE; METHYLPHENIDATE; MODAFINIL; OXYBATE SODIUM; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ARTICLE; ATTENTION DEFICIT DISORDER; CATAPLEXY; CHROMOSOME ABERRATION; CONGENITAL MALFORMATION; DAYTIME SOMNOLENCE; DRUG MILK LEVEL; GEOGRAPHIC DISTRIBUTION; HEALTH SURVEY; HUMAN; INTRAUTERINE GROWTH RETARDATION; MEDICAL PRACTICE; MEDICAL SPECIALIST; NARCOLEPSY; NONHUMAN; PATIENT CARE; PHYSICIAN; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; SLEEP DISORDER; SLEEP DISORDERED BREATHING; TERATOGENESIS; TIME TO PREGNANCY; VAGINAL DELIVERY; WORK EXPERIENCE;

EID: 84875627031     PISSN: 13899457     EISSN: 18785506     Source Type: Journal    
DOI: 10.1016/j.sleep.2012.11.021     Document Type: Article

References (105)

1. Dauvilliers Y., Arnulf I., Mignot E. Narcolepsy with cataplexy. Lancet 2007, 369(9560):499-511.
2. Fernández-Alonso A.M., Trabalón-Pastor M., Chedraui P., Pérez-López F.R. Factors related to insomnia and sleepiness in the late third trimester of pregnancy. Arch Gynecol Obstet 2012, 286(1):88-92.
3. Hoque R., Chesson A. Conception, pregnancy, delivery, and breastfeeding in a narcoleptic patient with cataplexy. J Clin Sleep Med 2008, 4(6):601-603.
4. Hoover-Stevens S., Kovacevic-Ristanovic R. Management of narcolepsy in pregnancy. Clin Neuropharmacol 2000, 23(4):175-181.
5. Maurovich Horvat E, Kemlink D, Högl B, Frauscher B, Ehrmann L, Geisler P, et al., Narcolepsy and pregnancy: a retrospective European evaluation of 249 pregnancies, 2012, in press.
6. Maurovich Horvat E., Tormaslova M., Slonkovia J., Kemlink D., Maurovich-Horvat L., NevŠímalová S., et al. Assessment of pregnancy outcomes in Czech and Slovak women with narcolepsy. Med Sci Monit 2010, 16(12):SR35-SR40.
7. Billiard M., Bassetti C., Dauvilliers Y., Dolenc-Groselj L., Lammers G.J., Mayer G., et al. EFNS guidelines on management of narcolepsy. Eur J Neurol 2006, 13(10):1035-1048.
8. Morgenthaler T.I., Kapur V.K., Brown T., Swick T.J., Alessi C., Aurora R.N., et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007, 30(12):1705-1711.
9. Koren G. Fetal risks of maternal pharmacotherapy: identifying signals. Handb Exp Pharmacol 2011, (205):285-294.
10. March of Dimes Birth Defects Foundation, 2001. Fact sheets: birth defects, miscarriage, and stillbirth; leading categories of birth defects; and perinatal profiles: statistics for monitoring state maternal and infant health. http://www.modimes.org.
11. Cephalon Prescribing Information. http://www.nuvigil.com/media/Full_Prescribing_Information.pdf.
12. Plessinger M.A. Prenatal exposure to amphetamines. Risks and adverse outcomes in pregnancy. Obstet Gynecol Clin North Am 1998, 25(1):119-138.
13. Milkovich L., van der Berg B.J. Effects of antenatal exposure to anorectic drugs. Am J Obstet Gynecol 1977, 129(6):637-642.
14. Naeye R.L. Maternal use of dextroamphetamine and growth of the fetus. Pharmacology 1983, 26(2):117-120.
15. Golub M., Costa L., Crofton K., Frank D., Fried P., Gladen P., et al. NTP-CERHR expert panel report on the reproductive and developmental toxicity of methylphenidate. Birth Defects Res B Dev Reprod Toxicol 2005, 74(4):300-381.
16. Heinonen O.P., Slone D., Shapiro S. Birth defects and drugs in pregnancy 1977, Publishing Sciences Group, Littleton, MA.
17. Humphreys C., Garcia-Bournissen F., Ito S., Koren G. Exposure to attention deficit hyperactivity disorder medications during pregnancy. Can Fam Physician 2007, 53(7):1153-1155.
18. FDA Joint Meeting of the Arthritis Advisory Committee (AAC) and Drug Safety and Risk Management (DSaRM) advisory committee. Bethesda, Maryland; 2010.
19. Kuczkowski K.M. Liquid ecstasy during pregnancy. Anaesthesia 2004, 59(9):926.
20. Moore K.L., Persaud T.V.N. The developing human: clinically oriented embryology 2003, W.B. Saunders, Philadelphia. 7th ed.
21. Soltanifar S., Russell R. Neuraxial anaesthesia for caesarean section in a patient with narcolepsy and cataplexy. Int J Obstet Anesth 2010, (4):440-443. Epub.
22. Williams S.F., Alvarez J.R., Pedro H.F., Apuzzio J.J. Glutaric aciduria type II and narcolepsy in pregnancy. Obstet Gynecol 2008, 111(2 Pt. 2):522-524.
23. Provigil Pregnancy Registry, 2012: http://provigilpregnancyregistry.com/.
24. EMA, Assessment report for modafinil containing medicinal products EMA/4038/2011, http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Modafinil_31/WC500105597.pdf.
25. Ping L.S., Yat F.S., Kwok W.Y. Status cataplecticus leading to the obstetric complication of prolonged labor. J Clin Sleep Med 2007, 3:56-57.
26. Burrow B., Burkle C., Warner D.O., Chini E.N. Postoperative outcome of patients with narcolepsy. A retrospective analysis. J Clin Anesth 2005, 17:21-25.
27. Bennett P.N. Use of the monographs on drugs. Drugs and human lactation 1996, 67-74. Elsevier, Amsterdam. P.N. Bennett (Ed.).
28. Altshuler L.L., Burt V.K., McMullen M., Hendrick V. Breastfeeding and sertraline: a 24-hour analysis. J Clin Psychiatry 1995, 56:243-245.
29. Pons G., Rey E., Matheson I. Excretion of psychoactive medications into breast milk. Clin Pharmacokinet 1990, 27:270-289.
30. Hackett L.P., Kristensen J.H., Hale T.W., Paterson R., Ilett K.F. Methylphenidate and breast-feeding. Ann Pharmacother 2006, 40:1890-1891.
31. Spigset O., Brede W.R., Zahlsen K. Excretion of methylphenidate in breast milk. Am J Psychiatry 2007, 164(2):348.
32. Spigset O., Carleborg L., Ohman R., Norstrom A. Excretion of citalopram in breast milk. J Clin Pharmacol 1997, 44:295-298.
33. Jensen P.N., Olesen O.V., Bertelsen A., Linet K. Citalopram and desmethylcitalopram concentrations in breast milk and in serum of mother and infant. Ther Medication Monit 1997, 19:236-239.
34. Koren G., Nordeng H. Antidepressant use during pregnancy: the benefit-risk ratio. Am J Obstet Gynecol 2012, 207(3):157-163.
35. Koziar V.S., Trofimov S.S., Ostrovskaia R.U., Sariev A.K., Zherdev V.P. Prenatal exposure to sodium oxybutyrate prevents a disorder of general behavior, learning and memory in the progeny of rats subjected to chronic hemic hypoxia. Eksp Klin Farmakol 1994, 57:8-11.
36. Trofimov S.S., Ostrovskaia R.U., Smol'nikova N.M., Kravchenko E.V., Kutepova O.A., Bondarenko N.A., et al. Sodium oxybutyrate normalizes the central nervous system functions in the progeny of rats subjected to hypobaric hypoxia during pregnancy. Eksp Klin Farmakol 1993, 56:8-11.
37. Kovalev G.I., Budygin E.A., Gainetdinov R.R., Kudrin V.S., Trofimov S.S., Ostrovskaia R.U. The sodium oxybutyrate and nooglutil correction of dopamine release in the striatum of prenatally alcoholized rat pups. Bull Eksp Biol Med 1993, 116:56-58.
38. Trofimov S.S., Ostrovskaia R.U., Smol'nikova N.M., Nemova E.P., Bobrova O.V., Koltovaia N.A., et al. A behavioral and biochemical analysis of the therapeutic effect of sodium oxybutyrate in alcoholic encephalopathy in progeny. Farmakol Toksikol 1991, 54:62-64.
39. Ostrovskaia R.U., Smol'nikova N.M., Savchenko N.M., Trofimov S.S., Nemova E.P. Sodium oxybutyrate correction of the disorders in higher nervous activity in the progeny of alcoholized animals. Farmakol Toksikol 1988, 51:89-94.
40. Hedner T., Lundborg P. Effect of gammahydroxybutyric acid on catecholamine synthesis and utilization in the developing rat brain. J Neural Transm 1982, 54:19-28.
41. Hedner T., Hedner J., Iversen K., Wessberg P., Lundborg P. Gammahydroxybutyric acid: central biochemical and behavioral effects in neonatal rats. Pharmacol Biochem Behav 1985, 23:185-189.
42. Sizov P.I., Iasnetsov V.S. Effect of sodium oxybutyrate on the development of uterine hyperactivity. Farmakol Toksikol 1984, 47:47-50.
43. Cosmi E.V., Morishima H.O., Daniel S.S., James L.S. Effect of sodium 4-hydroxybutyrate gamma-oh on fetal and newborn guinea pigs. Am J Obstet Gynecol 1968, 100:72-75.
44. Teo S., Khetani V., O'Neil R., Stirling D.I., Thomas S.D. Developmental toxicity of d-methylphenidate and dl-methylphenidate in rabbits following oral intubation. Toxicologist 2001, 60:219.
45. Stewart B.E., Stump D.G., Johnson P.A., Working P.K. Methylphenidate HCl is not a developmental toxicant in the rat. Toxicologist 2001, 60:219-220.
46. Teo S.K., Stirling D.I., Thomas S.D., Hoberman A.M., Christian M.S., Khetani V.D. The perinatal and postnatal toxicity of d-methylphenidate and d, l-methylphenidate in rats. Reprod Toxicol 2002, 16:353-366.
47. Teo S.K., Stirling D.I., Hoberman A.M., Christian M.S., Thomas S.D., Khetani V.D. d-Methylphenidate and d, l-methylphenidate are not developmental toxicants in rats and rabbits. Birth Defects Res B Dev Reprod Toxicol 2003, 68:162-171.
48. Gulati DK, Hope E, Mounce RC, Russell S. Methylphenidate. HCl reproduction and fertility assessment in Swiss CD-1 mice when administered via feed. Government Reports Announcements & Index 89 (15):190; 1989.
49. Gulati K, Hope E, Snell LM, Gilstrap LC 3rd. Methylphenidate hydrochloride. Environ Health Perspect 105 (Suppl 1):319-320; 1997 (see also NTP Report No. RACB88060, available through). http://ntp-server.niehs.nih.gov/.
50. Beckman D.A., Schneider M., Youreneff M., Tse F.L. Developmental toxicity assessment of d, d-methylphenidate and d-methylphenidate in rats and rabbits. Birth Defects Res B Dev Reprod Toxicol 2008, 83:489-501.
51. Takano K., Tanimura T., Nishimura H. Effects of some psychoactive drugs administered to pregnant mice upon the development of their offspring. Congenit Anom 1963, 3:13-25.
52. Chatterjee-Chakrabarty S., Miller B.T., Collins T.J., Nagamani M. Adverse effects of methylphenidate on the reproductive axis of adolescent female rats. Fertil Steril 2005, 84(Suppl 2):1131-1138.
53. Concerta Prescribing Information, 2012. http://www.concerta.net/adult/prescribing-information.html.
54. Oliverio A., Castellano C., Renzi P. Genotype or prenatal drug experience affect brain maturation in the mouse. Brain Res 1975, 90:357-360.
55. Ovcharov R, Todorov S. (Effect of some adrenergic substances on rabbit embryogenesis.) Izv-Durzh Inst Kontrol Lek Sredstva 9:101-7; 1976.
56. Yasuda M., Ariyuki F., Nishimura H. Effect of successive administration of amphetamine to pregnant mice upon the susceptibility of the offspring to the teratogenicity of thio-tepa. Congenit Anom 1967, 7:66-73.
57. Ching M., Tang L. Neuroleptic drug-induced alterations on neonatal growth and development I. Prenatal exposure influences birth size, mortality rate, and the neuroendocrine system. Biol Neonate 1986, 49:261-269.
58. Paget G.E. Dexamphetamine sulfate in mice. Lancet 1965, 2:1129.
59. Nora J., Vargo T.A., Nora A.H., Love K.E., McNamara D.G Malformation in mice induced by dexamphetamine sulfate. Lancet 1965, 2:1021-1022.
60. Kasirsky G., Tansy M.F. Teratogenic effects of methamphetamine in mice and rabbits. Teratology 1971, 4:131-134.
61. Acuff-Smith K.D., Vorhees C.V. Prenatal methamphetamine-induced functional neurotoxicity. Teratology 1991, 43:488-489.
62. Weissman A.D., Caldecott-Hazard S. In utero methamphetamine effects: I. Behavior and monoamine uptake sites in adult offspring. Synapse 1993, 13:241-250.
63. Burchfield D.J., Lucas V.W., Abrams R.M., Miller R.L., DeVane C.L. Disposition and pharmacodynamics of methamphetamine in pregnant sheep. JAMA 1991, 265:1968-1973.
64. Stek A.M., Fisher B.K., Baker R.S., Lang U., Tseng C.-Y., Clark K.E. Maternal and fetal cardiovascular responses to methamphetamine in the pregnant sheep. Am J Obstet Gynecol 1993, 169:888-897.
65. Stek A.M., Baker R.S., Fisher B.K., Lang U., Clark K.E. Fetal responses to maternal and fetal methamphetamine administration in sheep. Am J Obstet Gynecol 1995, 173:1592-1598.
66. Laget-Corsin L., Baroche J. L'anesthesie au gamma-hydroxybutyrate de sodium dans l'operation cesarienne. Anesth Anal Rean 1972, 29:43-49.
67. Van den Bogert A.G., Vree T.B., Van der Kleijn E., Damsma J. Placental transfer of 4-hydroxybutyric acid in man. Anaesthesiol Intensivmed 1978, 110:55-65.
68. DeBooy V.D., Seshia M.M., Tenenbein M., Casiro O.G. Intravenous pentazocine and methylphenidate abuse during pregnancy. Maternal lifestyle and infant outcome. Am J Dis Child 1993, 147:1062-1065.
69. Barlow A., Mullany B.C., Neault N., Davis Y., Billy T., Hastings R., et al. Examining correlates of methamphetamine and other drug use in pregnant American Indian adolescents. Am Indian Alsk Native Ment Health Res 2010, 17(1):1-24.
70. Oei J., Abdel-Latif M.E., Clark R., Craig F., Lui K. Short-term outcomes of mothers and infants exposed to antenatal amphetamines. Arch Dis Child Fetal Neonatal Ed 2010, 95(1):F36-F41.
71. McElhatton P.R. Fetal effects of substances of abuse. J Toxicol Clin Toxicol 2000, 38:194-195.
72. Good M.M., Solt I., Acuna J.G., Rotmensch S., Kim M.J. Methamphetamine use during pregnancy: maternal and neonatal implications. Obstet Gynecol 2010, 116(2 Pt. 1):330-334.
73. Eriksson M., Larsson G., Zetterström R. Amphetamine addiction and pregnancy II. Pregnancy, delivery and the neonatal period. Socio-medical aspects. Acta Obstet Gynecol Scand 1981, 60:253-259.
74. Gilbert E.F., Khoury G.H. Dextroamphetamine and congenital cardiac malformations. J Pediatr 1970, 76:638.
75. Matera R.F., Zabala H., Jimenez A.P. Bifid exencephalia. Teratogen action of amphetamine. Int Surg 1968, 50:79-85.
76. Bays J. Fetal vascular disruption with prenatal exposure to cocaine or methamphetamine [letter]. Pediatrics 1991, 87:416-418.
77. Nora J.J., Vargo T.A., Nora A.H., Love K.E., McNamara D.G, et al. Dexamphetamine: a possible environmental trigger in cardiovascular malformations. Lancet 1970, 1:1920.
78. Levin J.N. Amphetamine ingestion with biliary atresia. J Pediatr 1971, 79:130-131.
79. Milkovich L., Van den Berg B.J. Effects of antenatal exposure to anorectic drugs. Am J Obstet Gynecol 1977, 129:637-642.
80. Golub M.C., Crofton K., Frank D., Fried P., Gladen B., Henderson R., et al. NTP-CERHR expert panel report on the reproductive and developmental toxicity of amphetamine and methamphetamine. Birth Defects Res B 2005, 74:471-584. Also available at http://cerhr.niehs.nih.gov.
81. Nguyen D., Smith L.M., Lagasse L.L., Derauf C., Grant P., Shah R., et al. Intrauterine growth of infants exposed to prenatal methamphetamine: results from the infant development, environment, and lifestyle study. J Pediatr 2010, 157(2):337-339.
82. Little B.B., Snell L.M., Gilstrap L.C. Methamphetamine abuse during pregnancy: outcome and fetal effects. Obstet Gynecol 1988, 72:541-544.
83. Felix R.J., Chambers C.D., Dick L.M., Johnson K.A., Jones K.L. Prospective pregnancy outcome in women exposed to amphetamines. Teratology 2000, 61:441.
84. Draper E.S., Rankin J., Tonks A.M., Abrams K.R., Field D.J., Clarke M. Recreational drug use: a major risk factor for gastroschisis?. Am J Epidemiol 2008, 167(4):485-491.
85. Oro A.S., Dixon S.D. Perinatal cocaine and methamphetamine exposure: maternal and neonatal correlates. J Pediatr 1987, 111:571-578.
86. Smith L., Yonekura M.L., Wallace T., Berman N., Kuo J., Berkowitz C. Effects of prenatal methamphetamine exposure on fetal growth and drug withdrawal symptoms in infants born at term. J Dev Behav Pediatr 2003, 24:17-23.
87. Ladhani N.N., Shah P.S., Murphy K.E. Prenatal amphetamine exposure and birth outcomes: a systematic review and metaanalysis. Am J Obstet Gynecol 2011, 205(219):e1-e7. For the Knowledge Synthesis Group on Determinants of Preterm/LBW births.
88. Smith L.M., LaGasse L.L., Derauf C., Grant P., Shah R., Arria A., et al. The infant development, environment, and lifestyle study: effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth. Pediatrics 2006, 118(3):1149-1156.
89. Ramer C.M. The case of an infant born to an amphetamine addicted mother. Clin Pediatr 1974, 13:596-597.
90. Dahshan A. Prenatal exposure to methamphetamine presenting as neonatal cholestasis. J Clin Gastroenterol 2009, 43(1):88-90.
91. Roussotte F.F., Bramen J.E., Nunez S.C., Quandt L.C., Smith L., O'Connor M.J., et al. Abnormal brain activation during working memory in children with prenatal exposure to drugs of abuse: the effects of methamphetamine, alcohol, and polydrug exposure. Neuroimage 2011, 54(4):3067-3075.
92. Chang L., Cloak C., Jiang C.S., Farnham S., Tokeshi B., Buchthal S., et al. Altered neurometabolites and motor integration in children exposed to methamphetamine in utero. Neuroimage 2009, 48(2):391-397.
93. LaGasse L.L., Wouldes T., Newman E., Smith L.M., Shah R.Z., Derauf C., et al. Prenatal methamphetamine exposure and neonatal neurobehavioral outcome in the USA and New Zealand. Neurotoxicol Teratol 2011, 33(1):166-175.
94. Smith L.M., LaGasse L.L., Derauf C., Newman E., Shah R., Haning W., et al. Motor and cognitive outcomes through three years of age in children exposed to prenatal methamphetamine. Neurotoxicol Teratol 2011, 33(1):176-184.
95. Derauf C., LaGasse L., Smith L., Newman E., Shah R., Arria A., et al. Infant temperament and high-risk environment relate to behavior problems and language in toddlers. J Dev Behav Pediatr 2011, 32(2):125-135.
96. LaGasse L.L., Derauf C., Smith L.M., Newman E., Shah R., Neal C., et al. Prenatal methamphetamine exposure and childhood behavior at 3 and 5 years of age. Pediatrics 2012, 129(4):681-688.
97. Arria A.M., Derauf C., Lagasse L.L., Grant P., Shah R., Smith L., et al. Methamphetamine and other substance use during pregnancy: preliminary estimates from the infant development, environment, and lifestyle (IDEAL) study. Matern Child Health J 2006, 10(3):293-302.
98. Gray T.R., LaGasse L.L., Smith L.M., Derauf C., Grant P., Shah R., et al. Identification of prenatal amphetamines exposure by maternal interview and meconium toxicology in the Infant development, environment and lifestyle (IDEAL) study. Ther Drug Monit 2009, 31(6):769-775.
99. Hackett L.P., Ilett K.F., Kristensen J.H., Kohan R., Hale T.W. Infant dose and safety of breastfeeding for dexamphetamine and methylphenidate in mothers with attention deficit hyperactivity disorder: 40. [abstract]. Ther Drug Monit 2005, 27(2):220-221.
100. Data on file (DS-95-022). Frazer, PA: Cephalon, Inc.; 2012.
101. Steiner E., Villén T., Hallberg M., Rane A. Amphetamine secretion in breast milk. Eur J Clin Pharmacol 1984, 27:123-124.
102. Ayd F.J. Excretion of psychotropic drugs in human milk. Int Drug Ther News Bull 1973, 8:33-40.
103. Bartu A., Dusci L.J., Ilett K.F. Transfer of methylamphetamine and amphetamine into breast milk following recreational use of methylamphetamine. Br J Clin Pharmacol 2009, 67(4):455-459.
104. Committee on Drugs, American Academy of Pediatrics. The transfer of drugs and other chemicals into human breast milk. Pediatrics 2001;108:776-89.
105. ACOG. Committee Opinion No. 479: Methamphetamine abuse in women of reproductive age. Obstet Gynecol 2011;117(3):751-5.